Hoping to enter the cell therapy space, AstraZeneca has agreed to acquire Neogene Therapeutics in a deal worth up to US$320 M. The pharma giant will gain access to Neogene’s fully individualised T-cell receptor therapies (TCR-Ts) for oncology indications including solid tumours. The buyout shortly follows the announcement of AstraZeneca’s US$402 M licensing deal with C4X Discovery for the development and commercialisation of the latter’s oral NRF2 activator programme, with an initial focus on chronic obstructive pulmonary disease.